# A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

> **NCT00152386** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 950 (—)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Certolizumab pegol (CDP870)

## Key facts

- **NCT ID:** NCT00152386
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 950 (—)
- **Last updated:** 2020-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00152386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00152386, "A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00152386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*